Cancer Immunology, Immunotherapy

, Volume 57, Issue 7, pp 1007–1016 | Cite as

RETRACTED ARTICLE: Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF

  • Nobuto Yamamoto
  • Hirofumi Suyama
  • Hiroaki Nakazato
  • Nobuyuki Yamamoto
  • Yoshihiko Koga
Original Article

Abstract

Serum vitamin D binding protein (Gc protein) is the precursor for the principal macrophage-activating factor (MAF). The MAF precursor activity of serum Gc protein of colorectal cancer patients was lost or reduced because Gc protein is deglycosylated by serum α-N-acetylgalactosaminidase (Nagalase) secreted from cancerous cells. Deglycosylated Gc protein cannot be converted to MAF, leading to immunosuppression. Stepwise treatment of purified Gc protein with immobilized β-galactosidase and sialidase generated the most potent macrophage-activating factor (GcMAF) ever discovered, but it produces no side effect in humans. Macrophages treated with GcMAF (100 pg/ml) develop an enormous variation of receptors and are highly tumoricidal to a variety of cancers indiscriminately. Administration of 100 nanogram (ng)/human maximally activates systemic macrophages that can kill cancerous cells. Since the half-life of the activated macrophages is approximately 6 days, 100 ng GcMAF was administered weekly to eight nonanemic colorectal cancer patients who had previously received tumor-resection but still carried significant amounts of metastatic tumor cells. As GcMAF therapy progressed, the MAF precursor activities of all patients increased and conversely their serum Nagalase activities decreased. Since serum Nagalase is proportional to tumor burden, serum Nagalase activity was used as a prognostic index for time course analysis of GcMAF therapy. After 32–50 weekly administrations of 100 ng GcMAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells. During 7 years after the completion of GcMAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients.

Keywords

Colorectal cancer Macrophages Macrophage-activating factor Immunotherapy Deglycosylation α-N-acetylgalactosaminidase Immunosuppression 

Abbreviations

Gc

Human vitamin D3 binding protein

GcMAF

Enzymatically generated Gc-derived macrophage-activating factor

Nagalase

α-N-acetylgalactosaminidase

Notes

Acknowledgment

This investigation was supported in part by US Public Health Service Grant AI-32140 and Elsa U. Pardee Foundation Grant to N. Y.

References

  1. 1.
    Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 172:248–254CrossRefGoogle Scholar
  2. 2.
    Braun S, Pantel K (1999) Micrometastatic bone marrows involvement detection and prognostic significance. Med Oncol 16:154–165PubMedCrossRefGoogle Scholar
  3. 3.
    Cohen AM, Shank B, Friedman MA (1989) Colorectal cancer. In: Devita VT Jr, Hellman S, Rosenberg SA (eds) Cancer, principle and practice of oncology, 3rd edn. J.B. Lippincott, Philadelphia, pp 895–964Google Scholar
  4. 4.
    DeCosse JJ, Tsioulias GJ, Jacobson JS (1994) Colorectal cancer: detection, treatment and rehabilitation. CA Cancer J Clin 44:27–42PubMedCrossRefGoogle Scholar
  5. 5.
    Gleason DF (1977) The Veteran,s Administration Cooperative Urological Research Group: histological grading and clinical staging of prostate carcinoma. In: Tannenbaum M (ed) Urologic pathology: the prostate. Lea and Febiger, Philadelphia pp 171–198Google Scholar
  6. 6.
    Gold P, Freedman SQ (1965) Demonstration of tumor specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 121:439–462PubMedCrossRefPubMedCentralGoogle Scholar
  7. 7.
    Homma S, Yamamoto N (1990) Activation process of macrophages after in vitro treatment of mouse lymphocytes with dodecylglycerol. Clin Exp Immunol 79:307–313PubMedCrossRefPubMedCentralGoogle Scholar
  8. 8.
    Homma S, Yamamoto M, Yamamoto N (1993) Vitamin D binding protein (group-specific component, Gc) is the sole serum protein required for macrophage activation after treatment of peritoneal cells with lysophosphatidylcholine. Immunol Cell Biol 71:249–257PubMedCrossRefGoogle Scholar
  9. 9.
    Kanda S, Mochizuki Y, Miyata Y, Kanetake H, Yamamoto N (2002) Vitamin D-binding protein-derived macrophage activating factor, GcMAF, has an antiangiogenic activity both in vivo and in vitro. J Natl Cancer Inst 94:1311–1319PubMedCrossRefGoogle Scholar
  10. 10.
    Kisker O, Onizuka S, Becker CM, Fannon M, Flynn E, D’Amato R, Zetter B, Folkman J, Ray R, Swamy N, Pirie-Shepherd S (2003) Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. Neoplasia 5:32–40PubMedCrossRefPubMedCentralGoogle Scholar
  11. 11.
    Koga Y, Naraparaju VR, Yamamoto N (1999) Antitumor effects of vitamin D3-binding protein-derived macrophage activating factor on Ehrlich tumor bearing mice. Proc Soc Exp Biol Med 220:20–26PubMedCrossRefGoogle Scholar
  12. 12.
    Koprowski H, Herlyn M, Steplewski Z, Sears HF (1981) Specific antigen in serum of patients with colon carcinoma. Science 212:53–55PubMedCrossRefGoogle Scholar
  13. 13.
    Link RP, Perlman KL, Pierce EA, Schnoes HK, DeLuca HF (1986) Purification of human serum vitamin D-binding protein by 25-hydroxyvitamin D3-Sepharose chromatography. Anal Biochem 157:262–269PubMedCrossRefGoogle Scholar
  14. 14.
    Maehara Y, Kohnoe S, Sugimachi K (1990) Chemosensitivity test for carcinoma of digestive organs. Semin Surg Oncol 6:42–47PubMedCrossRefGoogle Scholar
  15. 15.
    Morton D, Eibler FR, Malmgren RA, Wood WC (1970) Immunological factors which influence response to immunotherapy in malignant melanoma. Surgery 68:158-164PubMedGoogle Scholar
  16. 16.
    Naraparaju VR, Yamamoto N (1994) Roles of ß-galactosidase of B lymphocytes and sialidase of T lymphocytes in inflammation-primed activation of macrophages. Immunol Lett 43:143–148PubMedCrossRefGoogle Scholar
  17. 17.
    Ngwenya BZ, Yamamoto N (1985) Activation of peritoneal macrophages by lysophosphatidylcholine. Biochim Biophys Acta 839:9-15PubMedCrossRefGoogle Scholar
  18. 18.
    Ngwenya BZ, Yamamoto N (1986) Effects of inflammation products on immune systems: lysophosphatidylcholine stimulates macrophages. Cancer Immunol Immunother 21:174–182PubMedCrossRefGoogle Scholar
  19. 19.
    Ngwenya BZ, Yamamoto N (1990) Contribution of lysophosphatidylcholine treated nonadherent cells to mechanism of macrophage activation. Proc Soc Exp Biol Med 193:118–124PubMedCrossRefGoogle Scholar
  20. 20.
    Olson RM, Perencevich NP, Malcolm AW, Chaffey JT, Wilson RE (1980) Pattern of recurrence following curative resection of adenocarinoma of the colon and rectum. Cancer 45:2969–2974PubMedCrossRefGoogle Scholar
  21. 21.
    Rich T, Gunderson LL, Lew R, Galdibini JJ, Cohen AM, Donaldson G (1983) Patterns of recurrence of rectal cancer after potentially curative surgery. Cancer 52:1317–1329PubMedCrossRefGoogle Scholar
  22. 22.
    Yamamoto N, Ngwenya BZ (1987) Activation of macrophages by lysophospholipids, and ether derivatives of neutral lipids and phospholipids. Cancer Res 47:2008-2013PubMedGoogle Scholar
  23. 23.
    Yamamoto N, Ngwenya BZ, Pieringer PA (1987) Activation of macrophages by ether analogues of lysophospholipids. Cancer Immunol Immunother 25:185–192PubMedCrossRefGoogle Scholar
  24. 24.
    Yamamoto N, St. Claire DA, Homma S, Ngwenya BZ (1988) Activation of mouse macrophages by alkylglycerols, inflammation products of cancerous tissues. Cancer Res 48:6044–6049PubMedGoogle Scholar
  25. 25.
    Yamamoto N, Homma S (1991) Vitamin D3 binding protein (group-specific component, Gc) is a precursor for the macrophage activating signal from lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci USA 88:8539–8543PubMedCrossRefPubMedCentralGoogle Scholar
  26. 26.
    Yamamoto N, Homma S, Haddad JG, Kowalski MN (1991) Vitamin D3 binding protein required for in vitro activation of macrophages after dodecylglycerol treatment of mouse peritoneal cells. Immunol 74:420–424Google Scholar
  27. 27.
    Yamamoto N, Homma S, Millman I (1991) Identification of the serum factor required for in vitro activation of macrophages: role of vitamin D binding protein (group-specific component, Gc) in lysophospholipid activation of mouse peritoneal macrophages. J Immunol 147:273–280PubMedGoogle Scholar
  28. 28.
    Yamamoto N (1993) In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor. US Patent number: 5,177,002Google Scholar
  29. 29.
    Yamamoto N, Kumashiro R (1993) Conversion of vitamin D3 binding protein (group-specific component) to a macrophage activating factor by the stepwise action of ß-galactosidase of B cells and sialidase of T cells. J Immunol 151:2794–2902PubMedGoogle Scholar
  30. 30.
    Yamamoto N, Kumashiro R, Yamamoto M, Willett NP, Lindsay DD (1993) Regulation of inflammation-primed activation of macrophages by two serum factors, vitamin D3-binding protein and albumin. Infect Immun 61:5388–5891PubMedPubMedCentralGoogle Scholar
  31. 31.
    Yamamoto N (1994) Macrophage activating factor from vitamin D binding protein. US Patent Number: 5,326,749Google Scholar
  32. 32.
    Yamamoto N, Naraparaju VR, Srinivasula SM (1995) Structural modification of serum vitamin D3-binding protein and immunosuppression in HIV-infected patients. AIDS Res Human Retrovirus 11:1373–1378CrossRefGoogle Scholar
  33. 33.
    Yamamoto N (1996) Structural definition of a potent macrophage activating factor derived from vitamin D3 binding protein with adjuvant activity for antibody production. Mol Immunol 33:1157–1164PubMedCrossRefGoogle Scholar
  34. 34.
    Yamamoto N, Naraparaju VR, Asbell SO (1996) Deglycosylation of serum vitamin D-binding protein and immunosuppression in cancer patients. Cancer Res 56:2827–2831PubMedGoogle Scholar
  35. 35.
    Yamamoto N (1997) Diagnostic and prognostic indices for cancer and AIDS. US Patent Number: 5,620,846Google Scholar
  36. 36.
    Yamamoto N, Naraparaju VR (1997) Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with vitamin D-binding protein-derived macrophage activating factor. Cancer Res 57:2187–2191PubMedGoogle Scholar
  37. 37.
    Yamamoto N, Naraparaju VR, Urade M (1997) Prognostic utility of serum a-N-acetylgalactosaminidase and immunosuppression resulted from deglycosylation of serum Gc protein in oral cancer patients. Cancer Res 57:295–299PubMedGoogle Scholar
  38. 38.
    Yamamoto N (1998) Vitamin D and the immune system. In: Delves PJ, Roitt I (eds) Encyclopedia of immunology, 2nd edn. Academic, London, pp 2494–2499CrossRefGoogle Scholar
  39. 39.
    Yamamoto N (1998) Diagnostic and prognostic ELISA assays of serum or plasma a-N-acetylgalactosaminidase for cancer. US Patent number: 5,712,104Google Scholar
  40. 40.
    Yamamoto N, Naraparaju VR (1998) Structurally well-defined macrophage activating factor derived from vitamin D3-binding protein has a potent adjuvant activity for immunization. Immunol Cell Biol 76:237–244PubMedCrossRefGoogle Scholar
  41. 41.
    Yamamoto N (2002) Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis. US Patent no. 6,410,269Google Scholar
  42. 42.
    Yamamoto N, Ueda M (2004) Eradication of HIV by treatment of HIV-infected/AIDS patients with vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF). Immunology 2000. Medmond Ltd, Bolonia, pp 197–200Google Scholar
  43. 43.
    Yamamoto N, Ueda M (2004) Therapeutic efficacy of vitamin D-binding protein (Gc protein)-derived macrophage activating factor (GcMAF) for prostate and breast cancers. Immunology 2000. Medmond Ltd, Bolonia, pp 201–204Google Scholar
  44. 44.
    Yamamoto N, Urade M (2005) Pathogenic significance of a-N-acetylgalactosaminidase found in the hemagglutinin of influenza virus. Microbes Infect 7:674–681PubMedCrossRefGoogle Scholar
  45. 45.
    Yamamoto N (2006) Pathogenic significance of a-N-acetylgalactosaminidase found in the envelope glycoprotein gp160 of human immunodeficiency virus type 1. AIDS Res Human Retrovirus 22:262–271CrossRefGoogle Scholar
  46. 46.
    Yamamoto N, Suyama H, Yamamoto N-Y, Ushijima N (2008) Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF). Int J Cancer 122:461–467PubMedCrossRefGoogle Scholar
  47. 47.
    Zbar B, Tanaka T (1971) Immunotherapy of cancer: regression of tumors after intralesional injection of living Mycobacterium bovis. Science 172:271-273PubMedCrossRefGoogle Scholar
  48. 48.
    Zhang S, Zhang HS, Cordon-Cardo C, Ragupathi G, Livingston PO (1998) Selection of tumor antigens as targets for immune attack using immunohistochemistry. III. Protein antigen. Clin Cancer Res 4:2669–2676PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Nobuto Yamamoto
    • 1
    • 5
  • Hirofumi Suyama
    • 2
  • Hiroaki Nakazato
    • 3
  • Nobuyuki Yamamoto
    • 1
  • Yoshihiko Koga
    • 4
  1. 1.Division of Cancer Immunology and Molecular ImmunologySocrates Institute for Therapeutic ImmunologyPhiladelphiaUSA
  2. 2.Nagasaki Immunotherapy Research GroupNagasakiJapan
  3. 3.Yokoyama Gastroenterology HospitalNagoyaJapan
  4. 4.Nakagawa HospitalFukuoka CityJapan
  5. 5.Division of Cancer Immunology and Molecular BiologySocrates Institute for Therapeutic ImmunologyPhiladelphiaUSA

Personalised recommendations